

Appl. No. 10/006,011
Amendment

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (cancelled).
2. (cancelled).
3. (cancelled).
4. (cancelled).
5. (cancelled).
6. (cancelled).
7. (cancelled).
8. (cancelled).
9. (cancelled).
10. (cancelled).
11. (cancelled).
12. (cancelled).
13. (cancelled).

Appl. No. 10/006,011
Amendment

14. (cancelled).

15. (currently amended) A pharmaceutical composition, comprising:

- a) a polypeptide consisting of the amino acid sequence SEQ ID NO:3 endorepellin, wherein ~~said endorepellin consists of amino acid residues 3687 to 4391 (SEQ ID NO:3) of perlecan (SEQ ID NO:2), or a an endorepellin fragment of said polypeptide which comprises the amino acid sequence SEQ ID NO:10 having and has angiogenesis-inhibiting activity, wherein said endorepellin fragment comprises amino acid residues 4182 to 4391 (SEQ ID NO:10) of perlecan; and~~
- b) a pharmaceutically acceptable carrier or excipient.

16. (canceled)

17. (canceled)

18. (currently amended) The pharmaceutical composition of claim 15, wherein said ~~endorepellin~~ fragment consists of the amino acid sequence SEQ ID NO:9 ~~residues 4108 to 4391 (SEQ ID NO:9) of perlecan.~~

19. (currently amended) The pharmaceutical composition of claim 15, wherein said ~~endorepellin~~ fragment consists of the amino acid sequence SEQ ID NO:10 ~~residues 4182 to 4391 (SEQ ID NO:10) of perlecan.~~